|
TUESDAY, DECEMBER 8, 2020 |
|
8:00 am - 8:15 am
|
WELCOME AND OPENING REMARKS |
|
|
|
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
|
|
| 8:15 am - 9:30 am |
| SPECIAL SESSION |
|
| |
Breast Cancer and COVID19
Moderator: Melissa L. Bondy, PhD
Stanford Medicine
Stanford, CA
|
|
| 8:15 am - 11:00 am |
SPECIAL SESSION - Presented by Tigerlily Foundation & AACR |
|
| |
Welcome: AACR & Tigerlily – Dr. Charles Perou & Mamah Karmo
Introduction: Setting the Stage for Health Equity, Collaboration and Partnership
Sean Johnson, Harvard University & Tigerlily Foundation Medical Advisory Board Member
Session 1: Socio-Economic Access Matters
Where You Live Matters: Impact of Economic, Racial/Ethnic, and Racialized Economic Residential Segregation on Breast Cancer Survival
Racial disparities persist despite with uptake of digital breast tomosynthesis (DBT) for breast cancer screening
Examining a Decade of Racial Disparity in Partial Mastectomy and Oncoplastic Surgery
Patient Voice (Panel Discussion): As it pertains to the posters just presented, while there have been so many investments in ending barriers, why do socio-economic disparities exist and what do you feel can be done to end disparities (economic, screening, surgical and in clinical trials)? Specifically, how do we reach the right people and eliminate implicit biases that may be impacting the black population?
General Audience Q&A: Open
Session 2: Not a One Size Fits All: Personalized Medicine for the Underserved
Comprehensive genomic and transcriptomic profiling of molecular subtypes reveal ancestral differences in the activity of signaling pathways between patients with African and European ancestry – FUNMI
Racial differences in breast cancer immune microenvironments
Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy – FUNMIs
Gene expression profiles of Ghanaian and Ethiopian Triple-Negative breast tumors
Patient Voice (Panel Discussion): As it pertains to the posters just presented, why is it important to work with diverse patient advocates to generate more evidence (real world and scientific research) that better informs genomic profiling, personal ancestry, differences in chemotherapy response, and genetic expression difference between various races – African, African American and European ancestry (brown people)?
General Audience Q&A: Open
Session 3: Policy Change to End Disparities
Did Medicaid expansion under the Affordable Care Act narrow the gap between American Indians and Whites on breast cancer management and prognosis?
Medicaid expansion associated with earlier stage and improved reconstruction rates in low income breast cancer patients (Ohio State Med center)
Impact of Medicaid expansion on racial disparities in time to adjuvant chemotherapy administration among breast cancer (BC) patients
The Affordable Care Act and Breast Cancer Stage at Presentation at an Urban Safety Net Hospital (Cook County Hospital and Rush med school in Chicago)
Comprehensive analysis of health services, sociodemographic, clinical, and genomic factors driving locally advanced breast cancer mortality via a first-in-kind linkage of SEER-Medicare data with physical tumor samples
Patient Voice (Panel Discussion): As it pertains to the posters just presented, how could these recommendations work to end health disparities, and how can patient advocates activate and collaborate with the scientific community to achieve state and Federal policy change?
General Audience Q&A: Open |
|
| |
|
|
| 9:30 am - 11:00 am |
WORKSHOPS |
|
| |
Clinical Research Workshop
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Research technology for clinicians (CTCs, cfDNA, Crispr)
Nicholas Turner, PhD, FRCP, BM, MA
The Royal Marsden Hospital
London, United Kingdom
Capturing patient reported outcomes
Oluwadamilola Fayanju, MD, MA, MPHS, FACS
Duke University School of Medicine
Durham, NC
Improving clinical trial design
Thomas Braun, PhD
University of Michigan School of Public Health
Ann Arbor, MI
Increasing clinical trial accrual
Deborah Collyar
Patient Advocates in Research (PAIR)
San Francisco, CA
FDA and Breast Cancer Workshop
Trastuzumab Deruxtecan
Preeti Narayan, MD
US Food and Drug Administration
Silver Spring, MD
Tucatinib
Mirat Shah
US Food and Drug Administration
Silver Spring, MD
Sacituzumab
Christy Osgood, MD
US Food and Drug Administration
Silver Spring, MD
|
|
| 9:30 am - 11:00 am |
SPECIAL SESSION |
|
| |
Global Breast Cancer Screening
Moderator: Ismail Jatoi, MD, PhD
UT Health San Antonio
San Antonio, TX
Breast cancer screening trials in low and middle income countries: Lessons learned
Rengaswamy Sankaranarayanan, MD, MBBS
RTI International
New Delhi, India
Weighing the benefits and harms of breast cancer screening
Philippe Autier, MD, MPH, PhD
International Prevention Research Institute
Dardilly, France
|
|
| |
|
|
| 10:00 am - 3:00 pm |
EXHIBITS
|
|
| |
|
|
| 11:00 am - 7:00 pm
|
EDUCATIONAL SESSIONS
Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees
with a better understanding of the background leading up to talks they
will hear in the succeeding days, and some of the techniques that will
be used. These presentations should also provide researchers with ideas
and techniques to be considered for their own studies.
|
|
| 11:00 am - 1:00 pm
|
Special Topics in ER+ Breast Cancer
Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN
Special topics in early stage ER breast cancer
David Cameron, MBBS, MD
The University of Edinburgh
Edinburgh, United Kingdom
Special topics in metastatic ER+ breast cancer
Ingrid Mayer, MD, MSc
Vanderbilt University Medical Center
Nashville, TN
Special topics in ER+ breast cancer: mechanisms of therapeutic resistance
Robert Clarke, PhD
Manchester Breast Centre
Manchester, United Kingdom
"Choosing Wisely" to Reduce the Toxicity and Burden of Radiation Therapy
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
Omitting radiotherapy in select situations
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI
Hypofractionated radiotherapy and emerging RT approaches
Jean L. Wright, MD
Johns Hopkins Medicine
Baltimore, MD
Strategies to reduce cardiac toxicity
Rachel B. Jimenez, MD
Massachusetts General Hospital
Boston, MA
Metastasis - A Moving Target
Moderator: Suzanne AW Fuqua, PhD
Baylor College of Medicine
Houston, TX
Evolution and heterogeneity
Andrea Bild, PhD
City of Hope
Monrovia, CA
EMT
Jing Yang, PhD
University of California San Diego
La Jolla, CA
Dormancy
Lewis Chodosh, MD, PhD
University of Pennsylvania
Philadelphia, PA
|
|
| 1:00 pm - 3:00 pm
|
Triple Negative Breast Cancer
Moderator: Rebecca Dent, MD, MSc
National Cancer Center Singapore
Duke-NUS Medical School
Singapore
Deconstructing TNBC
Rebecca Dent, MD, MSc
National Cancer Center Singapore
Duke-NUS Medical School
Singapore
State of the art treatment for neoadjuvant/adjuvant triple negative breast cancer
Lisa A. Carey, MD
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Metastatic TNBC – What’s new on the horizon?
Jennifer K. Litton, MD
UT MD Anderson Cancer Center
Houston, TX
How and when to use immunotherapy and related toxicities
Javier Cortes, MD, PhD
IOB Institute of Oncology, Madrid and Barcelona
Madrid, Spain
SABCS with the Society of Surgical Oncology present De-escalation of Surgical Therapy: What Does the Data Support
Moderator: Eleftherios P. Mamounas, MD, MPH
Orlando UF Health Cancer Center
Orlando, FL
DCIS
Pro
E. Shelley Hwang, MD, MPH
Duke University School of Medicine
Durham, NC
Con
Sarah McLaughlin, MD
Mayo Clinic
Jacksonville, FL
Exceptional responders to neoadjuvant chemotherapy
Pro
Joerg Heil, MD, PhD
University Hospital Heidelberg
Heidelberg, Germany
Con
Monica Morrow, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
DNA Damage Repair
Moderator: Andrea Richardson, MD, PhD
Johns Hopkins Medicine
Washington, DC
Rescue DNA repair pathway and tumor immunity
Manjeet K. Rao, PhD
UT Health San Antonio
San Antonio, TX
DNA repair defect as a driver of therapy resistance
Serena Nik-Zainal, MD, PhD
University of Cambridge
Cambridge, United Kingdom
Targeting DDR
Simon Boulton, PhD
Francis Crick Institute and Artios Pharma Ltd.
London, United Kingdom
|
|
| 3:00 pm - 5:00 pm
|
Personalized HER2 Targeted Therapy 2020 - Are We There?
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
HER2 targeted therapy: Determinates of response and mechanisms of resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Personalized treatment for early stage HER2-positive breast cancer
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain
Treatment of HER2-positive metastatic breast cancer - advances and challenges
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA
The Disparity Crisis in Breast Cancer
Moderator: Lisa Newman, MD. MPH
Weill Cornell Medicine/NYP Network
New York, NY
Tumor biology by race and ethnicity
John D. Carpten, PhD
Keck School of Medicine of USC
Los Angeles, CA
Population based trends
Julie R. Palmer, ScD
Boston University School of Public Health
Boston, MA
Treatment differences and consequences
Mariana Chavez MacGregor, MD, MSC
UT MD Anderson Cancer Center
Houston, TX
Genomic and Epigenomic Alterations in Resistance
Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
Chromosomal instability and tumor immunity
Mathieu Lupien, PhD
Princess Margaret Cancer Centre
Toronto, Canada
The unique epigenetic state of invasive lobular breast cancers
Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA
Targeting adaptive resistance
Gordon Mills, MD, PhD
Oregon Health Sciences University
Portland, OR
|
|
| 5:00 pm - 7:00 pm |
New Frontiers in Immunotherapy
Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX
Novel biomarkers in immune therapy response
Lajos Pusztai, MD, DPhil
Yale Cancer Center
New Haven, CT
New targets in myeloid cells
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX
Rationale for combination therapies (including pre-clinical data)
Sherene Loi, MBBS, FRACP, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia
Accelerating Recovery After Breast Cancer
Moderator: Susan Rafte
Community Advocate for Baylor College of Medicine Breast Center
Houston, TX
and
Mothaffar F. Rimawi, MD
Baylor College of Medicine
Houston, TX
Toxicities of breast cancer treatment
Nora Lynn Henry, MD, PhD
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Body image and sexual health
Ann H. Partridge, MD MPH
Dana-Farber Cancer Institute
Boston, MA
Oncofertility
Kathryn Ruddy, MD MPH
Mayo Clinic
Rochester, MN
Tumor Inflammation (and Metastasis)
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Tumor INF signaling - A double edged sword in cancer
Sandra S. McAllister, PhD
Harvard Medical School
Boston, MA
New insights to cancer-associated systemic inflammation
Karin de Visser, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands
Obesity, inflammation and breast cancer - what's new
Pamela Goodwin, MD, FRCPC, MSc
Mount SInai Hospital
Toronto, Canada
|
|
| |
|
|
| 7:30 pm - 10:00 pm |
OPEN SATELLITE EVENTS
|
|
|
|